AstraZeneca PT Raised to GBX 51 (AZN)
Stock analysts at Leerink Swann upped their target price on shares of AstraZeneca (LON:AZN) from GBX 50 ($0.81) to GBX 51 ($0.82) in a report issued on Monday, AR Network reports. The firm currently has a “market perform” rating on the stock. Leerink Swann’s price objective indicates a potential downside of 98.41% from the stock’s previous close.
AZN has been the subject of a number of other recent research reports. Analysts at Panmure Gordon reiterated a “hold” rating on shares of AstraZeneca (LON:AZN) in a research note to investors on Monday. They now have a GBX 3,200 ($51.63) price target on the stock. Separately, analysts at Deutsche Bank reiterated a “hold” rating on shares of AstraZeneca (LON:AZN) in a research note to investors on Monday. They now have a GBX 3,425 ($55.26) price target on the stock. Finally, analysts at AlphaValue reiterated a “reduce” rating on shares of AstraZeneca (LON:AZN) in a research note to investors on Thursday. They now have a GBX 3,256 ($52.53) price target on the stock. Eleven research analysts have rated the stock with a sell rating, fifteen have given a hold rating and five have assigned a buy rating to the stock. AstraZeneca currently has a consensus rating of “Hold” and an average target price of GBX 3,110.30 ($50.18).
AstraZeneca (LON:AZN) traded up 0.45% during mid-day trading on Monday, hitting GBX 3215.50. 2,262,389 shares of the company’s stock traded hands. AstraZeneca has a 52-week low of GBX 2786.00 and a 52-week high of GBX 3544.50. The stock has a 50-day moving average of GBX 3215.42 and a 200-day moving average of GBX 3252.57. The company’s market cap is £40.258 billion.
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.